Arsenal Biosciences
SOUTH SAN FRANCISCO, CA, United States · Biotechnology, Health Care, Therapeutics · 1,000 employees
Arsenal Biosciences, Inc. (ArsenalBio), headquartered in South San Francisco, Calif., is a privately held programmable cell therapy company discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer. Our full-stack R&D engine generates multifunctional T cell medicines, enabled by precise and specific CRISPR insertion of large synthetic DNA sequences. Arse
Funding history
- Funding Round — $325.4M — Sep 2024
- Series series c — $325.0M — Sep 2024
- Funding Round — $220.8M — Sep 2022
- Series series b — $220.0M — Sep 2022
Recent signals
- Sep 16, 2024: Nate Hardy Joins Arsenal Biosciences, Inc. as Chief Financial Officer
- Sep 04, 2024: Raised $325.4M
- Sep 04, 2024: Raised $325.0M in Series series c
- Sep 09, 2022: Raised $220.8M
- Sep 06, 2022: Raised $220.0M in Series series b
See plans & pricing → Track Arsenal Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.